Chemoradiotherapy Combined With Programmed Death 1 Antibody in Recurrent Nasopharyngeal Carcinoma: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Latest Information Update: 26 Apr 2022
At a glance
- Drugs Toripalimab (Primary) ; Cisplatin; Gemcitabine; Ropidoxuridine; Sintilimab
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
Most Recent Events
- 26 Apr 2022 New trial record